Glucocorticoids
(GCs) have a variety of effects on the brain including site-preferential, inhibitory effects on hippocampal neurons.
In the case of dexamethasone (DEX), extended rather than single-dose treatment in vivo may be required for binding to brain rather than peripheral (e.g., pituitary) GC receptors and for maximizing other biologic effects in hippocampus (e.g., GC receptor downregulation, inhibition of glucose transport).
Based on the contributory role of hippocampal neurons in declarative memory performance, we investigated the cognitive consequences of DEX treatment in normal adult human subjects, hypothesizing a decrease in declarative memory performance after extended but not overnight treatment. Double-blind, placebo-controlled treatment with DEX was given at 2300 hr for four consecutive days (0.5, 1, 1, 1 mg, respectively).
Plasma sampling (0800 and 1600 hr) and cognitive testing (1600 hr) were performed on study days 0 (baseline), 1, and 4, and 7 d posttreatment. Repeated-measures ANOVA found a significant interaction between study day and treatment condition for correct recall during a paragraph recall task [F(3,51) = 3.52, p = 0.021. DEX (n = 10) in comparison to placebo (n = 9) treatment decreased correct paragraph recall on study day 4 [F(1,17) = 5.01, p = 0.041 and study day 11 [F(1,17) = 5.82, p = 0.031, with the lowest level of performance occurring on day 4 followed by a return toward baseline performance level by day 11. In the placebo-treated subjects, correct paragraph recall improved over the course of treatment, consistent with practice. No other cognitive measure was affected by DEX treatment, arguing against a nonspecific DEX effect on arousal or attention.
Plasma cottisol concentrations were maximally suppressed at study day 4, consistent with GC receptor binding by DEX.
[Key words: glucocorticoid, cognitive, memory, declarative memory, dexamethasone, cortisol, hippocampus] Brief glucocorticoid (GC) exposure has been associated with a variety of physiologic and biochemical actions that can affect the brain, including the hippocampus. In some cases, site-pref-erential effects on hippocampal neurons versus neurons from other brain regions have been reported. Effects on hippocampal neurons include the site-preferential downregulation of hippocampal GC receptors (Sapolsky et al., 1984) , involution of the dendritic processes of hippocampal neurons (Woolley et al., 1990) , inhibition of long-term potentiation (Foy et al., 1987) and primed burst potentiation (Bennett et al., 199 1; Diamond et al., 1992) and the site-preferential inhibition ofglucose transport into hippocampal neurons and glia in a dose-and timedependent manner (Horner et al., 1990) . The relatively higher density of GC receptors in the hippocampus, as compared with other CNS sites, may contribute to the site-preferential nature of some of these GC effects (Reul and de Kloet, 1985; Magarinos et al., 1989; Horner et al., 1990) . However, the interpretation of these reports is complicated by the varying sensitivity of different regions or subfields within the hippocampus to specific effects (e.g., McEwen et al., 1992) . Further, relative binding to brain versus pituitary CC receptors in vivo has also been demonstrated to vary with the specific GC (e.g., synthetic vs endogenous), dose, and duration oftreatment (Spencer et al., 1990; Miller et al., 1992) . A range of evidence supports the description in primates of a medial-temporal lobe declarative memory system that underlies the acquisition and recall of facts and events over short intervals (i.e., periods up to several weeks) (for review, see Squire and Zola-Morgan, 199 1; Squire, 1992) . This system is composed of the hippocampus, along with adjacent entorhinal, parahippocampal, and perirhinal cortices. The acute effect of GCs on memory performance in nonprimate species has been reported as both facilitating (Flood et al., 1978) and detrimental (Bohus and de Wied, 1980; Borrell et al., 1984) . Early investigations also proposed a role for GCs and hippocampal CC receptors in the filtering of irrelevant stimuli by the hippocampus (McEwen, 1982) . However, the implications of these nonprimate findings for human declarative memory performance are complicated by varying species, dose level and timing, and task characteristics. In addition, the wide distribution of GC receptors in brain and the complex genomic and nongenomic actions of GCs suggest that hippocampal or extrahippocampal effects could lead to a disruption of declarative memory or other cognitive functions.
Few controlled studies of GC effects on cognition in humans are available. In a naturalistic study design, Bender et al. (199 1) reported decreased verbal memory performance during higherdose prednisone treatment of asthmatic children, as compared to lower doses. Investigators have also reported memory impairment (Mauri et al., 1993) as well as correlations between Impairment I" Memory Performance both plasma cortisol (CORT) and ACTH concentrations and memor> performance. in patients with Gushing's disease (Starkman et al., 1986) . In both investigations.
cognitive improvement was associated with the reduction of plasma CORT concentrations. In a controlled experimental design using dcxamethasone (DEX). prednisone. and placebo in normal adults and depressed patients, the administration ofboth GCs was linked to transient memory deficits (Wolkowitr ct al.. 1990 ). Thcsc deficits involt ed increased errors ofcommission.
but not omission, during a word list recall task (i.c., incorrect recall of distracter nerds along with correct recall of target words).
To test the hypothesis that GCs ha1.e an effect on differentiated elements of cognitive functioning in humans, v-c prospectively investigated the cognitive consequences of DEX treatment in normal adults. A preferential decrease in declarative memory performance. in comparison to other elements of cognitive performance. was predicted during 4 d of DEX treatment. Based on (1) the time course of changes in <K receptor binding following CC exposure (Sapolsky ct al., I984), (2) the time course of G<'-mcdiatcd changes in glucose transport (Homer ct al., 1990) . and (3) the results of studies of CC receptor activation in the rat suggesting that extended, rather than overnight, treatment with DEX is required for binding to hippocampal, in contrast to pituitary. CC receptors (Spencer et al.. 1990: Miller ct al., l992) , we further hlpothesired that a decrease in declarative memory performance would not bc detectable until the fourth (vs the first) day of DEX treatment.
Materials and Methods
Cognitive testing and plasma sampling were pcrformcd before. during. and after a 4 d pcrlod of double-blind.
placebo-controlled treatment with dexamethasone in normal adults (n = 19). On study days O-3 at 2300 hr, subjects rcccived either oral DEX (n = IO), in successive doses of 0.5. 1. I. and 1 mg, or matched placebo capsules (n = 9). Blood samples were obtained at 0800 and 1600 hr on da13 0 (baseline). I, 4, and I I (7 d recover? condition). Cogniti\c lesting was performed immechately after the 1600 hr blood drawing on stud) da)s 0 (baseline), 1, 4, and I I. All subjects in the experiment were evaluated for subjectivell perceived adverse events at the completion of the protocol. A single subject dropped out of the protocol after the baseline assessment and first night of treatment complaining of adverse cognitive effects; this subject had been assigned to the placebo condition and was not included in the analysis. One subject assigned to the DEX condition was unable to complete the day 11 assessment because of a farnIl) emergency:
this subject denied any advcrsc events.
Sub~ms.
All subjects gave wsritten informed consent for their participation and were employees or students from the Washington (Carroll et al.. 1981; Priviteraet al.. 1982; SwartL and Dunner, 1982; Ravi et al., 1984) . Subjects were also excluded for any condition known to interfere \vith cognitlvc performance or contraindicate glucocortlcold use (e.g.. neurologlcal disorders. including any histon of significant head inJun. defined as a loss of consciousness for 2 5 mln and/or with neurologic scquclae).
In addition, subjects not routinely sleeping during nighttime hours \\erc cxcludcd from study. in an effort to standardire circadian cycles for all Subjects. Handedness was measured for all subjects using a validated. normed In\-entory to dctcr-mine a decile score (Oldfield. 197 I ) . in order to assess a potential confound to cognitix e performance (Gcschwind and Galabur-da, 1987 (Wechsler, 1987) . One paragraph was gi\.en at each test session; scores for correct recall were tabulated using established scoring methods (Kussell. 1975; Gangarosa et al., 11388) . Total scores for (I) correct verbatim recall of paragraph bits as well as (2) commission errors (combining both intrusions and perseverations into a single summed score) were tabulated for both the immediate and delayed recall condition.
(2) A serial addition task was used as one measure of attention. The task (Gronwall and Wrightson, 1974) (4) The integrity of visuoperceptual function was assessed using the Benton line orientation task (Benton et al., 1983) . Subjects are first shown a template of 11 numbered lines of different orientations. Subsequent pictures, each consisting of two of these lines without numbers, are presented with the template for correct identification of the number that should accompany each line. Each test has five sets of unnumbered lines with errors scored as the number of incorrectly identified lines.
DEX and CORT measurement. Plasma was immediately separated from whole blood by centrifugation and stored at -80°C prior to assay. CORT concentrations were measured by radioimmunoassay using a commercial kit from ICN Biomedicals (Costa Mesa, CA). For the measurement of plasma DEX concentrations, the radioimmunoassay protocol described by Ritchie et al. (1990) was employed using an antiserum (IgG-dexamethasone-I) supplied by IgG Corporation (Nashville, TN) and a tracer (1, 2, 4, 6, supplied by New England Nuclear (Boston, MA). The separation buffer contained a 16 mg'100 ml concentration of silica gel to enhance the separation ofbound from unbound ligand. After addition of separation buffer to each tube, tubes were centrifuged at 3000 x g at 4°C for 20 min.
Analysis. The effects of DEX and placebo treatment on cognitive performance were assessed using repeated-measures ANOVA to evaluate the overall effect of study day for specific cognitive measures comparing both treatment conditions (i.e., DEX vs placebo treatment). The following cognitive variables were tested: paragraph bits correctly recalled in the immediate and delayed recall condition, commission errors in the immediate and delayed recall condition, errors in the serial addition task, errors in the vigilance task, and errors in the line orientation task. Because the paragraph recall task includes both an immediate and a delayed recall condition where performance is to some degree related across conditions, three-way, repeated-measures ANOVA (recall condition x treatment condition x study day) was used to test empirically for separable effects of treatment on the immediate versus delayed measures of both correct recall performance and commission errors. The other cognitive measures were evaluated using two-way, repeated-measures ANOVA (treatment condition x study day). A comparison of cognitive performance during DEX versus placebo treatment on each separate study day (e.g., paired ANOVA comparing vigilance errors across treatment condition for each study day) was also planned as warranted by the results of the initial ANOVA, in order to test for the hypothesized time course for the DEX effect (i.e., detectable at study day 4). A critical value of p = 0.05 was used in evaluating all comparisons. The comparability of the DEX-versus placebo-treated groups was assessed using unpaired t test comparisons among the demographic variables (e.g., age, number of years of education). Finally, possible confounds to the primary analysis, such as the effect of age, and plasma CORT or DEX levels, were explored using Spearman's correlation estimates between specific measures of interest.
Results
Age of subjects, number of years of education, and handedness scores did not differ significantly between the DEX-and placebo-treated groups [mean ? SD: age (t = 1.96) 38.3 + 10.2 vs 29.4 ? 9.4; years of schooling (t = 0.54) 16.5 -+ 1.4 vs 15.9 ? 3.3; handedness score (t = 0.08) 3.3 f 4.0 vs 3.1 +-5.4, respectively]. The ratio of males to females in the DEX-and placebo-treated groups (4:6 and 4:5, respectively) was also comparable. Repeated-measures ANOVA revealed a significant interaction between treatment condition and study day [F(3,5 1) = 3.52, p = 0.021 for correct recall during the paragraph recall task. Mean correct scores for immediate and delayed recall, comparing DEX and placebo treatment, are shown in Figures  1 and 2 . No significant interactions were found in the ANOVA evaluating commission errors in the paragraph recall task, or in the ANOVAs evaluating error scores for any other cognitive task, consistent with no significant overall effect of treatment on cognitive performance for any of these measures.
DEX, and not placebo, treatment resulted in a parallel decrease in both the immediate and delayed measure of correct paragraph recall, followed by posttreatment recovery to baseline levels. No significant interactions were found between recall condition (immediate vs delayed) and either treatment condition or study day (two-way interactions).
Further, no significant interaction was found among recall condition, treatment condition, and study day (three-way interaction), consistent with no significant separable effect of treatment on correct recall performance across the recall conditions. Consequently, immediate and delayed correct recall scores were collapsed (by summing the scores for immediate and delayed bits recalled) into a single et al. -Glucocortlcold-induced impairment III Memory Performance overall correct recall score for use in the next part ofthc analysis. Paired ANOVA comparing this overall correct recall measure during DEX versus placebo treatment for each study day found a significant diflerence between treatment conditions on study day 4 [E( 1.17) = 5.0 I. /I = 0.041 and study day 11 [F(l 1 17) = 5.82, p = 0.031 only. These differences are consistent with the hypothesized time for detection ofthe DEX effect and with an extended decrcmcnt in recall performance following DEX treatment. When asked about subjectively perceived adverse events at the completion of the experiment. no subject reported any cognitive, psychological.
or other effects. Plasma CORT concentrations in the DEX-treated subjects were maximally suppressed at study day 4, consistent with GC receptor binding by DEX. The mean plasma DEX concentration \.alue approximately doubled from study day, 1 to study day 4: these \-alues were within or just above. respectively. the prcviously reported range obtained in humans at 0800 hr after a single I mg DEX dose at 2300 hr (Low! and Meltrcr, 1987) . In the total study sample, plasma CORT concentrations were significantly correlated with immediate (r, = 0.48. p ( 0.05) and delayed (r$ = 0.48. p < 0.05) recall performance on study day 4 and delayed recall performance (r\ = 0.60. ~7 <: 0.05) on study day 11, reflecting higher plasma CORT concentrations and recall scores in <ubjects taking placebo: no similar relationships were found in the DEX-treated subjects alone (i.e., where the decreases in memoc performance were found). No other relationships between plasma CORT concentrations and other measures of cognitive performance on any study day were found in the total study sample or DEX-treated subjects. An inverse relationship nas found betvveen age and baseline 0800 (r, = ~0.78, p < 0.001) and 1800 hr (r$ = -m0.51. p < 0.05) plasma CORT concentrations in the total sample. Age. number of years of education, and handedness scores were generally unrelated to cogniti1.e performance in the total sample. although baseline error scores on the line orientation task were correlated vvith age (ri = 0.53. p < 0.05). and baseline immediate recall pcrformancc was related to the number of years of education (r, = 0.51. p ( 0.05) . No significant effects of subject gender were found. Although the sample size for the DEXtrcatcd subjects was small, an exploratory inspection ofthc data found no strong relationships between plasma DEX concentrations and cognitive performance on any* study day. a moderately strong negative relationship between subjects' age and day I post-DEX CORT concentrations at 1800 hr only (Y, = ~0.74, y < 0.05), and no relationship between age and plasma DEX concentrations or between age and cognitive performance during DEX treatment.
Discussion
The results ofthis investigation suggest an impairment ofverbal dcclarati1.e memory performance in normal adult human subjects after relatively low-dose and brief DEX treatment. The performance deficits found on the paragraph recall task do not appear to reflect a generalized deficit in attention or arousal. Although performance on this memory task is also dependent on other cognitive functions such as intact organizational and learning capacities. earlier investigations have strongly related paragraph recall performance to the integrity of the mcdialtemporal lobe declarative memory system that includes hippocampus (for review, see Squire. 1992) . However. this investigation did not assess some other aspects of higher cognitilc function (e.g.. procedural memory). leaving the selectivity ofthe DEX effect for declarativ-e memory performance uncertain. The results strengthen previous evidence of a GC-mediated memory deficit in humans. reported during DEX and prednisonc treatment (Wolkovvitz et al., 1990: Bender et al.. I99 1) and in relation to plasma CORT concentration in patients with Gushing's disease (Starkman et al.. 1986) . Wolkowitz et al. (I 990) had previously reported CC trcatmerit-related errors ofcommission during a word list recall task. The present experiment found omission but not commission errors during DE.X treatment. Both comtnission and omission errors have been associated with hippocampal and mcdial-temporal memory system dysfunction (Squire. 1987; Crosson et al.; . The use of young normal subjects in the present experimcnt (minimizing the incidence of commission errors) as well as diffcrcnces between the word list and paragraph recall tasks (Lezak. 1983 ) may account for the diffcrcnces in results. Future studies should attempt to clarify the effect of GC treatment on errors of omission versus commission using subjects of varying age and more than one mcasurc of performance.
While the sample size for this experiment was small. outliers did not explain the findings; the delay-ed Jcdl data for indiv idual subjects. comparing study days I and 4. showed decreasing performance for 7 of the 10 subjects receiving DEX. However, no clinical (e.g.. gender) or plasma measure (e.g.. DEX concentration) was rclatcd to cognitive outcotne in the secondary analyses of the smaller sample receiving DEX, and a type II error could have occurred. In addition. the baseline error rate for the nonmemory tasks in the present experiment was low. suggesting that the tasks could have been overlearned and less sensitive to detrimental effects. Future studies should address the specificity of the GC effect on declarative memory in contrast to nondeclarativc mcmov performance (e.g.. priming) or nonmemory elements of cognitil~e performance using additional memory tasks and more complex nonmcmon measures. Giv.en the wide distribution of GC receptors in brain and the complex genomic and nongenomic actions of GCs, it is possible that either hippocampal or e?.trahippocatnpal effects could lead to a disruption ofdeclarativc memory performance. The underlying hvpothesis that CC treatment may preferentially affect the functioning of hippocampus versus other brain regions remains to be tested by direct measures of neuronal function.
In the placebo-treated subjects, paragraph recall performance improved over the course of treatment, consistent with a practice effect. In contrast, DEX-treated subjects did not show an overall improvement in paragraph recall performance during the trial. This difference may reflect either (I) a prolonged effect of DEX on declarative memory performance (e.g., see Table I : note that DEX concentrations were still detectable on study day I I). (2) a DEX-induced impairment in procedural memory. that retarded task learning, such that treated subjects were slower than controls in manifesting practice-related improvement. or (3) less of a final test session improvement in the DEX-treated group due to less proactive interference during the earlier test sessions in this group (see below). The improv~ement in paragraph recall performance in the placebo-treated subjects was most notable between study days 4 and I I. and may have been due to the rclativ-ely longer interv.al between test sessions resulting in a release from the deleterious effect of proactive interference caused by recent cognitive testing (Craik. 1977) . Proactive interference tends to be associated uith better memory performance (ic., better recall from test session to test session leads to more potential interference from prel iouslv pre- sented material), and would be expected to be greater in the with the cognitive effect. However, further experiments are obplacebo-treated subjects in this experiment. Similarly, the imviously required to better determine the relationship of DEX provement in performance that should accompany the release versus CORT to cognitive function (see below). The plasma from proactive interference would also be expected to be greater DEX measurements did provide evidence for subject compliin the placebo-treated subjects.
ance with self-administered DEX doses. It is also possible that DEX itself was not directly responsible for the cognitive effect but acted to lower plasma CORT concentrations. Reduced CORT concentrations in brain might be hypothesized to explain directly the cognitive effect. Although this idea may be weakened by the data from patients with Cushing's disease (Starkman et al., 1986; Mauri et al., 1993) , the CORT-based hypothesis is supported by reports that DEX does not readily enter the brain and suppresses CORT at the level of the pituitary following overnight treatment (e.g., Miller et al., 1992) . However, longer treatment with DEX was not a part of this or other studies reporting this conclusion. In contrast, another CC receptor activation study suggests that extended (1, 2, and 3 d), rather than overnight, in viva treatment with DEX is required for binding to hippocampal rather than peripheral GC receptors (Spencer et al., 1990) . Entry of DEX into brain at these doses (selected to produce plasma concentrations in the range seen in humans following overnight 1 mg treatment) is notably time dependent.
Consistent with the time course for DEX entry into the rat brain during similar treatment, the effect on recall performance in humans was detectable after DEX treatment for 4 d but not overnight. In contrast, plasma CORT concentrations were markedly suppressed by the overnight treatment with 0.5 mg of DEX and had returned to baseline levels by day 11 (see Table  I ), suggesting a temporal dissociation between effects on plasma CORT concentration and cognitive function. Consistent with the time course for the decrease in recall performance, the mean plasma DEX concentration value approximately doubled from study day 1 to study day 4 (the mean value at day 4 was just above the previously reported range obtained in humans at 0800 hr after a single 1 mg DEX dose at 2300 hr) (Lowy and Meltzer, 1987) . In sum, (1) the present experiment should have offered sufficient treatment time for DEX binding to brain (e.g., hippocampus), and (2) changes in plasma DEX, rather than plasma CORT, concentration appear to be more temporally consistent This investigation was limited by the use of DEX as the only steroid treatment; other steroid hormones (i.e., CORT, progesterone, testosterone) could have had similar effects on memory performance. However, precursors for both androgenic and estrogenic steroids (Flood et al., 1992) as well as estrogenic steroids themselves (Phillips and Sherwin, 1992) have been reported to have enhancing effects on memory performance. Both DEX and prednisone produced the same detrimental effect in the word list recall paradigm used by Wolkowitz et al. (1990) , although differences in the effect of different GCs on memory performance have been found in animal experiments (Micco and McEwen, 1980; Bohus and de Kloet, 198 1) . The constant DEX dose following the first study day prevented a dose-response relationship from being explored and limited the variance in plasma DEX concentrations in this experiment. However, plasma CORT concentrations, an index of DEX activity, were correlated with day 4 memory performance across the total subject sample (i.e., subjects receiving both DEX and placebo); this is consistent with the lower CORT levels and memory scores found in the DEX-treated group (no similar relationship was found in the DEX-treated subjects alone).
The exploratory analyses found an inverse relationship between subjects' age and day 1 1800 hr post-DEX CORT concentrations, suggesting increased plasma DEX concentrations in older subjects. Although previous investigators have reported a direct correlation between age and plasma CORT concentrations (Oxenkrug et al., 1983) , the small sample size of DEXtreated subjects, the generally younger age of the subjects, and the doses of DEX used in this investigation may explain this discrepancy. This experiment did not measure ACTH and related secretagogues that may be altered by DEX treatment and may affect memory performance (McGaugh, 1983) . The direction of the ACTH-related cognitive effect appears to be dependent on dose and the specific cognitive paradigm (Gold and Delanoy, 1981) . Finally, potential confounds to the interpre-et al. * Glucocortlcoid-Induced Impairment i n Memory Performance tation of the primary analysis were not found in the correlational analyses of any relevant variables. The neurobiological mechanism underlying the impairment in delayed recall performance during DEX treatment in humans remains to be studied. From a "hypothesis-generating" perspective, this declarative memory deficit is consistent with a preferential GC effect on hippocampal neurons. However, nonhippocampal effects or a secondary effect of reduced CORT cannot be excluded. Future investigations should address the specificity of the findings with an expanded cognitive battery, along with different steroids and variables doses, including stressphysiologic doses of CORT. If a deleterious effect of CORT on declarative memory performance were confirmed, this would suggest the possibility of a causal component in the previously reported associations between plasma CORT concentrations and memory impairment in a variety of neuropsychiatric diseases such as Cushing's disease (Whelan et al., 1980; Starkman et al., 1986) Alzheimer's disease (Jenike and Albert, 1984) schizophrenia (Newcomer et al., 1991) and depression (see Reus, 1984, for review) .
